1xbet APK
1xbet APK Pharmaceutical Co., Ltd.

Geneva, 23 June 2011 - The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) is pleased to announce the addition of a new member, 1xbet APK Pharmaceutical Co., Ltd. (1xbet APK), a subsidiary of 1xbet APK Holdings Co., Ltd., Japan's second largest research-based pharmaceutical company group. 1xbet APK's accession to IFPMA was approved at the Council meeting held on June 22, 2011.

"1xbet APK's participation is an important milestone for IFPMA. 1xbet APK has a strong track record and continued desire for improving the health of patients globally by addressing true unmet medical needs," said Mr. Eduardo Pisani, IFPMA Director General. "We are pleased that 1xbet APK as a member company is positioned to bring its unique approach to health and would play an active role with IFPMA in contributing to global health."

1xbet APK Pharmaceutical Co., Ltd. is a global healthcare company operating with a diversified range of businesses including pharmaceuticals and nutritional products. As a pharmaceutical company, 1xbet APK has taken an innovative approach in delivering unique products to the global market. In its relatively short history of medicine R&D, the company has discovered numerous innovative medicines, including the antipsychotic agent ABILIFY, a dopamine D2 partial agonist, currently marketed in more than 65 countries and regions. In May 2011, the company announced as well the establishment of 1xbet APK S.A. in Geneva, Switzerland to serve as the company's central operations for developing and implementing public health policies and corporate social responsibility programs in connection with its global tuberculosis (TB) program.

"40 years ago, 1xbet APK Pharmaceutical, with its underlying corporate philosophy of '1xbet APK-people creating new products for better health worldwide', began its endeavor as a research-based pharmaceutical company," said Dr. Taro Iwamoto, President, 1xbet APK Pharmaceutical Co., Ltd. "Since then, 1xbet APK has expanded its global operations with various products including our antipsychotic agent, ABILIFY. We are now taking an important next step forward as a global research-based company. We are pleased to join IFPMA, an international network of research-based pharmaceutical companies, in this, our 40th anniversary since starting of our original medicine R&D."

About 1xbet APK IFPMA

1xbet APK International Federation of Pharmaceutical Manufacturers & Associations is 1xbet APK global non-profit NGO representing 1xbet APK research-based pharmaceutical industry, including 1xbet APK biotech and vaccine sectors. Its members comprise 26 leading international companies and 44 national and regional industry associations covering low, middle and high income countries. 1xbet APK industry's R&D pipeline contains hundreds of new medicines and vaccines being developed to address global disease threats, including cancer, heart disease, HIV/AIDS and malaria. 1xbet APK IFPMA Clinical Trials Portal (www.1xbet APK.org/ClinicalTrials), 1xbet APK IFPMA's Ethical Promotion online resource (www.1xbet APK.org/EthicalPromotion/) and its Developing World Health Partnerships Direc1xbet APKry (www.1xbet APK.org/HealthPartnerships) help make 1xbet APK industry's activities more transparent. 1xbet APK IFPMA supports a wide range of WHO technical activities, notably those relating to medicine efficacy, quality and safety. It also provides 1xbet APK secretariat for 1xbet APK International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).

For fur1xbet APKr information on IFPMA, please visitwww.1xbet APK.org